Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.730 +0.120 (+2.14%)
Streaming Delayed Price Updated: 12:56 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Unusual volume stocks are being observed in Monday's session.
These stocks have an unusual volume in today's session 
Via Chartmill
Which stocks are experiencing notable movement on Friday?
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
What's going on in today's session
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
11 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Crude Oil Dips 7%; ISM Services PMI Falls In March
 
Via Benzinga
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic
Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with... 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
These stocks that are showing activity before the opening bell on Thursday.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall
 
Via Benzinga
Topics Stocks
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission. 
Via Benzinga
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in  
Via Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly 
Via InvestorPlace
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reproxalap, an investigational drug  
Via Benzinga
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
What's Going On With Aldeyra Therapeutics Stock?
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares are trading higher Wednesday after the company announced that it entered into an exclusive opti 
Via Benzinga
Why Are Stocks Up Today?
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. 
Via InvestorPlace
Topics Economy
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.